title: Comparison of the immune responses in children vaccinated with three strains of BCG vaccine.
abstract: The present study was conducted to evaluate and compare the specific cellular responses of children vaccinated with three different strains of BCG. The study comprised of normal children with normal weight and normal general responses (PHA) to in vitro leukocyte migration inhibition test (LMIT). The three strains of BCG under study were Japan-BCG, Glaxo-BCG and Madras-BCG. One hundred children were selected at random from each group. The mean ages of these infants were 9.9 +/- 9.5, 9.8 +/- 7.6 and 9.8 +/- 8.3 weeks, respectively. Six weeks after vaccination, the diameter (in mm) of induration at the vaccination site was measured. Three months after vaccination, in vitro LMIT was performed against PPD tuberculin antigen. This test was done again after 3 months in all the children who tested negative. The mean value of the diameter of the Glaxo-BCG group (10.0 +/- 13.5 mm) was significantly higher (p < 0.05) than the mean values of Japan-BCG (9.10 +/- 3.9 mm) and Madras-BCG (8.38 +/- 4.1 mm). The mean LMI values were similar in all the three groups. There was no correlation between the in vitro and in vivo parameters. The number of children positive to LMI (PPD) were 59, 58 and 63, for the Madras, Japan and Glaxo-BCG groups, respectively. A total number of 91, 91 and 95 were positive to LMIT at the end of 6 months after BCG in the Madras, Japan and Glaxo-BCG groups, respectively. The observations suggested that there were no major differences between the three strains of BCG in their capacity to induce cellular responses.
authors.affiliation: Bhagvan Mahavir Medical Research Centre, Mahavir Marg, Hyderabad.
authors.forename: V
authors.initials: V
authors.lastname: Vijayalakshmi
authors.forename: K J
authors.initials: KJ
authors.lastname: Murthy
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: A L
authors.initials: AL
authors.lastname: Kiran
mesh_terms: D000704:Analysis of Variance; D001500:BCG Vaccine / Q000008:administration & dosage / Q000145:classification*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control; D014611:Vaccination
chemical_list: D001500:BCG Vaccine